Allovectin-7 therapy in metastatic melanoma

Agop Y. Bedikian, Michele Del Vecchio

Research output: Contribution to journalArticlepeer-review


Background: Patients with metastatic melanoma are immunosuppressed by the growing tumor. Allovectin-7 therapy is a form of active immunotherapy that aims at immunization of the host with substances designed to elicit an immune reaction that will eliminate or slow down the growth and spread of the cancer. Objective: to describe the rationale for immunotherapy with Allovectin-7 and assess its safety profile and efficacy based on the results of completed melanoma clinical trials. Methods: we reviewed both the published medical literature and the results of trials pending publication. Results/conclusion: Allovectin-7 is a safe and active immunotherapeutic agent. It induces local and systemic durable responses in patients with metastatic melanoma.

Original languageEnglish
Pages (from-to)839-844
Number of pages6
JournalExpert Opinion on Biological Therapy
Issue number6
Publication statusPublished - Jun 2008


  • Allovectin-7
  • DNA vaccination
  • Immunotherapy
  • Melanoma

ASJC Scopus subject areas

  • Pharmacology
  • Biochemistry, Genetics and Molecular Biology(all)
  • Genetics
  • Immunology


Dive into the research topics of 'Allovectin-7 therapy in metastatic melanoma'. Together they form a unique fingerprint.

Cite this